MILAN, Italy and NEW YORK , May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A . (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for
No dose limiting toxicity observed in previous three dose level cohorts Represents a 50% higher dose than highest prior level Update of guidance for trial MILAN, Italy and NEW YORK , May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering
Initial evidence of potential to modulate tumor microenvironment MILAN, Italy and NEW YORK , May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer,
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK , April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of
*** David Reardon, Luigi Naldini, Brad Loncar *** MILAN, Italy and NEW YORK , April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will
Data to be presented at the 2022 annual meeting of American Association for Cancer Research MILAN, Italy and NEW YORK , March 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell
MILAN, Italy and NEW YORK , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that management will be participating in
MILAN, Italy and NEW YORK , Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A . (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™,
MILAN, Italy and NEW YORK , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™, announced today the
MILAN (Italy)/NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno- gene therapy for cancer (Temferon™), announced today that it will be presenting updated preliminary Phase I/II clinical data on
